Literature DB >> 26070918

Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.

Mark Lawler1, Rick Kaplan2, Richard H Wilson3, Tim Maughan4.   

Abstract

Mesh:

Year:  2015        PMID: 26070918      PMCID: PMC4524758          DOI: 10.1634/theoncologist.2015-0014

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  13 in total

Review 1.  Role of randomized phase III trials in an era of effective targeted therapies.

Authors:  Manish R Sharma; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

3.  UK and US governments to fund personalised medicine.

Authors:  Talha Burki
Journal:  Lancet Oncol       Date:  2015-02-06       Impact factor: 41.316

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Molecular analysis for therapy choice: NCI MATCH.

Authors:  Barbara A Conley; James H Doroshow
Journal:  Semin Oncol       Date:  2014-05-22       Impact factor: 4.929

6.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

7.  More multiarm randomised trials of superiority are needed.

Authors:  Mahesh K B Parmar; James Carpenter; Matthew R Sydes
Journal:  Lancet       Date:  2014-07-26       Impact factor: 79.321

8.  Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

Authors:  Matthew R Sydes; Mahesh K B Parmar; Malcolm D Mason; Noel W Clarke; Claire Amos; John Anderson; Johann de Bono; David P Dearnaley; John Dwyer; Charlene Green; Gordana Jovic; Alastair W S Ritchie; J Martin Russell; Karen Sanders; George Thalmann; Nicholas D James
Journal:  Trials       Date:  2012-09-15       Impact factor: 2.279

9.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

10.  Speeding up the evaluation of new agents in cancer.

Authors:  Mahesh K B Parmar; Friederike M-S Barthel; Matthew Sydes; Ruth Langley; Rick Kaplan; Elizabeth Eisenhauer; Mark Brady; Nicholas James; Michael A Bookman; Ann-Marie Swart; Wendi Qian; Patrick Royston
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

View more
  8 in total

Review 1.  Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.

Authors:  Thomas M Caparrotta; James W Dear; Helen M Colhoun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

2.  Communicating About Precision Oncology.

Authors:  Daniel C McFarland; Elizabeth Blackler; Smita Banerjee; Jimmie Holland
Journal:  JCO Precis Oncol       Date:  2017-08-07

3.  Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.

Authors:  Mark Lawler; Anna Gavin; Manuel Salto-Tellez; Richard D Kennedy; Sandra Van Schaeybroeck; Richard H Wilson; Denis Paul Harkin; Margaret Grayson; Ruth E Boyd; Peter W Hamilton; Darragh G McArt; Jacqueline James; Tracy Robson; Robert D Ladner; Kevin M Prise; Joe M O'Sullivan; Timothy Harrison; Liam Murray; Patrick G Johnston; David J Waugh
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

4.  Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.

Authors:  Philip D Dunne; Paul G O'Reilly; Helen G Coleman; Ronan T Gray; Daniel B Longley; Patrick G Johnston; Manuel Salto-Tellez; Mark Lawler; Darragh G McArt
Journal:  Oncotarget       Date:  2016-06-14

Review 5.  Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.

Authors:  Mark Lawler; Deborah Alsina; Richard A Adams; Annie S Anderson; Gina Brown; Nicola S Fearnhead; Stephen W Fenwick; Stephen P Halloran; Daniel Hochhauser; Mark A Hull; Viktor H Koelzer; Angus G K McNair; Kevin J Monahan; Inke Näthke; Christine Norton; Marco R Novelli; Robert J C Steele; Anne L Thomas; Lisa M Wilde; Richard H Wilson; Ian Tomlinson
Journal:  Gut       Date:  2018-01       Impact factor: 23.059

Review 6.  Imaging biomarker roadmap for cancer studies.

Authors:  James P B O'Connor; Eric O Aboagye; Judith E Adams; Hugo J W L Aerts; Sally F Barrington; Ambros J Beer; Ronald Boellaard; Sarah E Bohndiek; Michael Brady; Gina Brown; David L Buckley; Thomas L Chenevert; Laurence P Clarke; Sandra Collette; Gary J Cook; Nandita M deSouza; John C Dickson; Caroline Dive; Jeffrey L Evelhoch; Corinne Faivre-Finn; Ferdia A Gallagher; Fiona J Gilbert; Robert J Gillies; Vicky Goh; John R Griffiths; Ashley M Groves; Steve Halligan; Adrian L Harris; David J Hawkes; Otto S Hoekstra; Erich P Huang; Brian F Hutton; Edward F Jackson; Gordon C Jayson; Andrew Jones; Dow-Mu Koh; Denis Lacombe; Philippe Lambin; Nathalie Lassau; Martin O Leach; Ting-Yim Lee; Edward L Leen; Jason S Lewis; Yan Liu; Mark F Lythgoe; Prakash Manoharan; Ross J Maxwell; Kenneth A Miles; Bruno Morgan; Steve Morris; Tony Ng; Anwar R Padhani; Geoff J M Parker; Mike Partridge; Arvind P Pathak; Andrew C Peet; Shonit Punwani; Andrew R Reynolds; Simon P Robinson; Lalitha K Shankar; Ricky A Sharma; Dmitry Soloviev; Sigrid Stroobants; Daniel C Sullivan; Stuart A Taylor; Paul S Tofts; Gillian M Tozer; Marcel van Herk; Simon Walker-Samuel; James Wason; Kaye J Williams; Paul Workman; Thomas E Yankeelov; Kevin M Brindle; Lisa M McShane; Alan Jackson; John C Waterton
Journal:  Nat Rev Clin Oncol       Date:  2016-10-11       Impact factor: 66.675

7.  Precision medicine: the foundation of future cancer therapeutics.

Authors:  Seung Ho Shin; Ann M Bode; Zigang Dong
Journal:  NPJ Precis Oncol       Date:  2017-04-24

8.  Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.

Authors:  Matthew Alderdice; Susan D Richman; Simon Gollins; James P Stewart; Chris Hurt; Richard Adams; Amy Mb McCorry; Aideen C Roddy; Dale Vimalachandran; Claudio Isella; Enzo Medico; Tim Maughan; Darragh G McArt; Mark Lawler; Philip D Dunne
Journal:  J Pathol       Date:  2018-03-25       Impact factor: 7.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.